Ramin Tadayoni, MD, PhD and Caroline Baumal, MD
Show Description +
As we approach the US FDA's decision on pegcetacoplan (Apellis Pharmaceuticals) for the treatment of geographic atrophy, Clinical Minute: Retina host Ramin Tadayoni, MD, PhD, sits down with Caroline Baumal, MD, to explore data from the phase 3 DERBY and OAKS studies. What conclusions can be reached now that 24-month data have been released—and will they affect treatment paradigms if pegcetacoplan is approved for marketing?
Posted: 10/18/2022
Ramin Tadayoni, MD, PhD and Caroline Baumal, MD
As we approach the US FDA's decision on pegcetacoplan (Apellis Pharmaceuticals) for the treatment of geographic atrophy, Clinical Minute: Retina host Ramin Tadayoni, MD, PhD, sits down with Caroline Baumal, MD, to explore data from the phase 3 DERBY and OAKS studies. What conclusions can be reached now that 24-month data have been released—and will they affect treatment paradigms if pegcetacoplan is approved for marketing?
Posted: 10/18/2022
Please log in to leave a comment.